Recro Pharma (REPH) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday morning. They currently have $8.25 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Other research analysts have also recently issued reports about the company. Oppenheimer set a $18.00 target price on Recro Pharma and gave the company a buy rating in a research note on Wednesday, August 8th. ValuEngine raised Recro Pharma from a hold rating to a buy rating in a research note on Tuesday. Finally, Janney Montgomery Scott set a $13.00 target price on Recro Pharma and gave the company a buy rating in a research note on Monday, October 1st. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $12.88.

NASDAQ:REPH traded up $0.16 on Wednesday, reaching $7.35. The company’s stock had a trading volume of 115,626 shares, compared to its average volume of 150,519. Recro Pharma has a 1-year low of $4.78 and a 1-year high of $13.05. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22. The stock has a market cap of $151.04 million, a price-to-earnings ratio of -3.69 and a beta of -0.51.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Recro Pharma had a negative return on equity of 194.05% and a negative net margin of 79.42%. The firm had revenue of $18.28 million during the quarter, compared to analysts’ expectations of $16.77 million. Sell-side analysts forecast that Recro Pharma will post -2.51 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of REPH. Cubist Systematic Strategies LLC acquired a new position in shares of Recro Pharma during the first quarter worth about $139,000. Oppenheimer & Co. Inc. acquired a new position in shares of Recro Pharma during the second quarter worth about $154,000. Monarch Partners Asset Management LLC acquired a new position in shares of Recro Pharma during the second quarter worth about $178,000. GSA Capital Partners LLP acquired a new position in shares of Recro Pharma during the second quarter worth about $206,000. Finally, Alambic Investment Management L.P. boosted its position in shares of Recro Pharma by 378.0% during the second quarter. Alambic Investment Management L.P. now owns 47,990 shares of the specialty pharmaceutical company’s stock worth $241,000 after buying an additional 37,950 shares during the period. 54.79% of the stock is owned by institutional investors.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: Bull Market

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply